Advertisement
BayerHealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. haveannounced that the Ministry of Health, Labour and Welfare in Japan hasapproved Nexavar(R) (sorafenib) tablets for the treatment of patients withunresectable hepatocellular carcinoma (HCC), a type of liver cancer thataccounts for 95 percent of all liver cancer cases in Japan(1). Nexavar isalso currently available in Japan as an approved treatment for unresectable ormetastatic renal cell carcinoma (RCC).
Advertisement
Advertisement